Integrated Filing — IndAS

General information about company
Scrip Code	544172
NSE Symbol	INDGN
MSEI Symbol	NOTLISTED
ISIN	INE065X01017
Name of company	Indegene Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	28-Apr-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	21-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Where financial results contain both consolidated financial results and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results.
Start date and time of board meeting	28-Apr-2025   17:30:00
End date and time of board meeting	28-Apr-2025   17:53:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2024-03-25
Indicate Company website link for updated RPT policy of the Company	https://www.indegene.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
No external loans and debt securities held by Company

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	2667000000	10936000000
	Other income	352000000	904000000
	Total income	3019000000	11840000000
2	Expenses
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	1845000000	7592000000
(e)	Finance costs	15000000	62000000
(f)	Depreciation, depletion and amortisation expense	69000000	262000000
(f)	Other Expenses
1	Other Expenses	426000000	1539000000
	Total other expenses	426000000	1539000000
	Total expenses	2355000000	9455000000
3	Total profit before exceptional items and tax	664000000	2385000000
4	Exceptional items	0	0
5	Total profit before tax	664000000	2385000000
6	Tax expense
7	Current tax	174000000	630000000
8	Deferred tax	-52000000	-58000000
9	Total tax expenses	122000000	572000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	542000000	1813000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	542000000	1813000000
17	Other comprehensive income net of taxes	-24000000	-13000000
18	Total Comprehensive Income for the period	518000000	1800000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	479000000	479000000
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve		18403000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	2.26	7.64
	Diluted earnings (loss) per share from continuing operations	2.25	7.59
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	2.26	7.64
	Diluted earnings (loss) per share from continuing and discontinued operations	2.25	7.59
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		Notes to the Statement of Standalone Financial Results for quarter and year ended 31 March 2025 nAll amounts in INR millions, except share data and where otherwise stated n1. The above Standalone Financial Results of the Company have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 the Regulations. Due to rounding off, the numbers presented throughout may not add up precisely to the totals. in the financial information denote amounts less than INR0.50 million. n2. The above Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 April 2025. The figures for the quarter ended 31 March 2025, are the balancing figures between audited figures in respect of full financial year and published unaudited year to date figures upto the end of the third quarter of the current financial year, which were subject to limited review. n3. The Standalone Financial Results for the quarter and year ended 31 March 2025, are available on the National Stock Exchange of India Limited URL www.nseindia.com, the BSE Limited website URL www.bseindia.com and on the Company's website URL www.indegene.cominvestorrelations. n4. During the year, the Company has completed Initial Public Offer IPO of 40,766,550 equity shares of face value of INR2 each at an issue price of INR452 per share Issue price of INR422, including a share premium of INR420 per share, for employee quota towards fresh issue, comprising fresh issue of 16,833,818 shares aggregating to INR7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR10,818. The equity shares of the Company are listed in National Stock Exchange of India Limited NSE and BSE Limited BSE on 13 May 2024. The Company has received an amount of INR7,244 net of Company's share of IPO expenses of INR356, retained in the Public Offer Account to the extent unpaid from the proceeds of the fresh issue. Out of the Company's shares of IPO expenses INR319 has been adjusted to securities premium. The utilization of IPO proceeds of INR7,244 is summarized below n

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	528000000
	Capital work-in-progress	36000000
	Investment property
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development
	Biological assets other than bearer plants
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	4713000000
	Trade receivables, non-current
	Loans, non-current	3635000000
	Other non-current financial assets	83000000
	Total non-current financial assets	8431000000
	Deferred tax assets (net)	216000000
	Other non-current assets	106000000
	Total non-current assets	9317000000
2	Current assets
	Inventories	0
	Current financial asset
	Current investments	5033000000
	Trade receivables, current	4184000000
	Cash and cash equivalents	352000000
	Bank balance other than cash and cash equivalents	1284000000
	Loans, current	408000000
	Other current financial assets	323000000
	Total current financial assets	11584000000
	Current tax assets (net)
	Other current assets	596000000
	Total current assets	12180000000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	21497000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	479000000
	Other equity	18403000000
	Total equity attributable to owners of parent	18882000000
	Non controlling interest
	Total equity	18882000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	135000000
	Total non-current financial liabilities	135000000
	Provisions, non-current	585000000
	Deferred tax liabilities (net)
	Deferred government grants, Non-current
	Other non-current liabilities
	Total non-current liabilities	720000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	0
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	17000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	331000000
	Total Trade payable	348000000
	Other current financial liabilities	837000000
	Total current financial liabilities	1185000000
	Other current liabilities	230000000
	Provisions, current	469000000
	Current tax liabilities (Net)	11000000
	Deferred government grants, Current
	Total current liabilities	1895000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	2615000000
	Total equity and liabilites	21497000000
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block

Textual Information(1)

The utilization of IPO proceeds of INR7,244 is summarized below nParticulars, Amount to be utilised as per offer document, Utilisation as on 31032025, Unutilised as on 31032025, Amounts in INR na. Repaymentprepayment of indebtedness of one of our Subsidiaries, ILSL Holdings, Inc. 3913, 3950, negative 37 nb. Funding the capital expenditure requirements of our Company and our Material Subsidiary, Indegene, Inc. 1029, 185, 844 nc. General corporate purposes and inorganic growth 2302, 2088, 214 nThe Company has repaid loan of USD 47.20 Million INR3950 outstanding in the books of ILSL Holdings Inc. material subsidiary, in line with Object 1 of the offer document. The amount utilised over and above the maximum amount specified as per the offer document is due to exchange rate fluctuation as on the date of offer document and as on the date of payment. nOut of the net proceeds which were unutilised as at 31 March 2025, INR980 are temporarily invested in fixed deposits, INR41 is held in the Companys monitoring account, while the balance amount is held in the public offer account towards the Company s share of expenses related to issue. n n5. During the year ended 31 March 2025, 521,330 options have been granted under Employee Restricted Stock Unit plan 2020 RSU 2020, 243,973 options have been granted under Employee Stock Option Plan 2020 ESOP 2020 and 39,571 options have been granted under Company Share Option Plan 2022 CSOP 2022 to the eligible employee of the Company. 527,331 options under RSU 2020 plan and 211,722 options under ESOP 2020 plan have been exercised during the year. n6. During the year ended 31 March 2025, the Company sold its wholly owned subsidiary Indegene Japan LLC to another wholly owned subsidiary Indegene Ireland Limited for a consideration of INR130, thereby Indegene Japan LLC becoming a step down subsidiary with effect from 22 January 2025. n7. Refer note in segment tab. n8. The Board of Directors, in its meeting on 28 April 2025, have proposed a final dividend of INR2 per equity shares for the financial year ended 31 March 2025. The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved, would result in a cash outflow of approximately INR480. n nNotes to Assets and Liabilites na. Property, plant and equipment includes Rightofuse assets of INR243. nb. Other noncurrent asset consists of Noncurrent tax assets net of INR102 and Other noncurrent asset of INR4. nc. Trade receivables, current consists Unbilled revenue of INR79. nd. Other non current financial liabilities consists of lease liabilities of INR 135. ne. Other current financial liabilities consists of lease liabilities INR 137 and other financial liabilities of INR 700. n

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments	Textual Information(2)

Text Block

Textual Information(2)

9. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. n nStatement of Cash Flow includes following aggregations: n nI.Cash flows from Operating Activities: n1. Other adjustments to reconcile profit loss includes na. Net gain on disposal or fair valuation of investments negative INR 292 nb. Reversals of provision for diminution in value of loans and interest negative INR 5 nc. Expected credit loss provision on trade receivables and advances INR 3 n2. Other adjustments for which cash effects are investing or financing cash flow consists of Net gain on sale of investments in subsidiaries negative INR 36 n nII.Cash flows from Investing Activities nI. Other Inflow Outflows of cash includes na. Purchase of investments accounted using FVTPL negative INR 6024 nb. Proceeds from redemption of investments INR 3667 nc. Investments in fixed deposits negative INR 18168 nd. Redemption or maturity of fixed deposit INR 16908 n nIII. Cash receipts from repayment of advances and loans made to other parties includes repayment of loan from related party. n nIV. Cash advances and loans made to other parties includes loan to related party. n n3. Cash flows from Financing Activities nProceeds from issuing shares is net of share issue expenses n

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of defined benefit obligation	-39000000	-21000000
	Total Amount of items that will not be reclassified to profit and loss	-39000000	-21000000
2	Income tax relating to items that will not be reclassified to profit or loss	-10000000	-5000000
3	Amount of items that will be reclassified to profit and loss
1	Exchange differences on translating the financial statements of foreign operation	5000000	3000000
	Total Amount of items that will be reclassified to profit and loss	5000000	3000000
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-24000000	-13000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Unaudited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			2385000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			58000000
	Adjustments for decrease (increase) in inventories			0
	Adjustments for decrease (increase) in trade receivables, current			-428000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			521000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			0
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-236000000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			262000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			157000000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-3000000
	Adjustments for dividend income			0
	Adjustments for interest income			464000000
	Adjustments for share-based payments			74000000
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			-36000000
	Other adjustments to reconcile profit (loss)			-294000000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-389000000
	Net cash flows from (used in) operations			1996000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			706000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			1290000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			130000000
	Other cash payments to acquire equity or debt instruments of other entities			953000000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			0
	Purchase of property, plant and equipment			165000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			3950000000
	Cash receipts from repayment of advances and loans made to other parties			2000000
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			306000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-3617000000
	Net cash flows from (used in) investing activities	-8247000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			7328000000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			0
	Payments of lease liabilities			155000000
	Dividends paid			0
	Interest paid			0
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			7173000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			216000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			4000000
	Net increase (decrease) in cash and cash equivalents			220000000
	Cash and cash equivalents cash flow statement at beginning of period			132000000
	Cash and cash equivalents cash flow statement at end of period			352000000

Signatory Details
Name of signatory	Srishti Ramesh Kaushik
Designation of person	Company Secretary and Compliance Officer
Place	Bangalore
Date	28-Apr-2025